Recro Pharma Analysis
Recro Pharma is undervalued with Real Value of 0.0 and Hype Value of 0.0. The main objective of Recro Pharma delisted stock analysis is to determine its intrinsic value, which is an estimate of what Recro Pharma is worth, separate from its market price. There are two main types of Recro Pharma's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Recro Pharma's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Recro Pharma's stock to identify patterns and trends that may indicate its future price movements.
The Recro Pharma stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Recro Pharma is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Recro Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Recro Pharma's ongoing operational relationships across important fundamental and technical indicators.
Recro |
Recro Stock Analysis Notes
About 65.0% of the company shares are owned by institutional investors. The book value of Recro Pharma was at this time reported as 0.95. The company recorded a loss per share of 0.57. Recro Pharma had not issued any dividends in recent years. The entity had a split on the 22nd of November 2019. Recro Pharma, Inc., a contract development and manufacturing organization, engages in the development, manufacturing, and packaging of oral solid dose drug products in the United States and internationally. Recro Pharma, Inc. was incorporated in 2007 and is based in Malvern, Pennsylvania. Recro Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 185 people. To find out more about Recro Pharma contact Geraldine Henwood at 770-534-8239 or learn more at https://www.recrogainesville.com.Recro Pharma Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more delisted stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Recro Pharma's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Recro Pharma or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Recro Pharma is not yet fully synchronised with the market data | |
| Recro Pharma has some characteristics of a very speculative penny stock | |
| Recro Pharma has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 62.97 M. Net Loss for the year was (20.68 M) with profit before overhead, payroll, taxes, and interest of 12.37 M. | |
| About 65.0% of the company shares are owned by institutional investors |
Recro Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 97.89 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Recro Pharma's market, we take the total number of its shares issued and multiply it by Recro Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Recro Profitablity
Recro Pharma's profitability indicators refer to fundamental financial ratios that showcase Recro Pharma's ability to generate income relative to its revenue or operating costs. If, let's say, Recro Pharma is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Recro Pharma's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Recro Pharma's profitability requires more research than a typical breakdown of Recro Pharma's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (32.85) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (12.58) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $12.58.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Recro Pharma to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Theme Ratings Now
Theme RatingsDetermine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |
| All Next | Launch Module |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Other Consideration for investing in Recro Stock
If you are still planning to invest in Recro Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Recro Pharma's history and understand the potential risks before investing.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |